Verona Pharma plc Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Revenue, net
Product sales, net
Other revenue
Total revenue, net
Cost of sales
Gross profit
Operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Total operating expenses
Operating loss
Other income/(expense):
Research and development tax credit
Loss on extinguishment of debt
Interest income
Fair value movement on warrants
Interest expense
Foreign exchange (loss)/gain
Total other (expense)/income, net
Loss before income taxes
Income tax expense
Net loss
Foreign currency translation adjustments
Total comprehensive loss attributable to shareholders of the Company
Loss per share, basic and diluted (in dollars per share)
Loss per ordinary share, basic (in dollars per share)
Loss per ordinary share, diluted (in dollars per share)
Weighted-average shares outstanding - basic (in shares)
Weighted-average shares outstanding - diluted (in shares)

Comments